The ProstatID, an adjunctive artificial intelligence software that radiologists can utilize with traditional magnetic resonance imaging (MRI), reportedly measures prostate gland volume, and suggests PI-RADS scoring of suspicious lesions.
An emerging artificial intelligence (AI) software program that may enhance the efficiency and accuracy of prostate cancer diagnosis has received 510(k) clearance from the Food and Drug Administration (FDA).
Through computer-aided detection (CAD), ProstatID™ (Bot Image) offers a colorized translucent overlay of two-dimensional axial T2 magnetic resonance imaging (MRI) to identify soft tissue lesions that may warrant closer inspection for potential malignancy. The ProstatID algorithm also utilizes the Prostate Imaging Reporting and Data System (PI-RADS) to score the cancer probability of suspicious lesions, according to Bot Image. The company noted that two internal studies showed improved accuracy and a reduced false positive rate with the use of ProstatID.
While other technologies have enhanced formatting and segmentation of MRI images of the prostate, Bot Image said ProstatID is a significant advance for the diagnosis of prostate cancer.
“Prostate cancer screening and detection methods adoption (have) changed little over the past 30 years despite the mountain of evidence pointing to the efficacy of superior technologies and the futility of the old methods,” noted Bot Image founder and CEO Randall W. Jones, Ph.D. “Sadly, this has resulted in the unnecessary and premature deaths of countless numbers of men in the (United States) alone. ProstatID represents an exciting step in the fight to save lives.”
Bot Image noted that ProstatID is available to radiologists as a software as a service (SaaS) tool, which provides secure, HIPAA compliant connectivity between a cloud-based ProstatID server and a facility’s radiology department server.
Leading Breast Radiologists Discuss the USPSTF Breast Cancer Screening Recommendations
May 17th 2024In recognition of National Women’s Health Week, Dana Bonaminio, MD, Amy Patel, MD, and Stacy Smith-Foley, MD, shared their thoughts and perspectives on the recently updated breast cancer screening recommendations from the United States Preventive Services Task Force (USPSTF).
CT Study: AI Algorithm Comparable to Radiologists in Differentiating Small Renal Masses
May 14th 2024An emerging deep learning algorithm had a lower AUC and sensitivity than urological radiologists for differentiating between small renal masses on computed tomography (CT) scans but had a 21 percent higher sensitivity rate than non-urological radiologists, according to new research.
Current Insights and Emerging Roles for Contrast-Enhanced Mammography
May 10th 2024In a recent lecture at the 2024 ARRS Annual Meeting, Jordana Phillips, MD, discussed the role of contrast-enhanced mammography in staging breast cancer, evaluating response to neoadjuvant chemotherapy and recalls from screening.
ACR Collaborative Model Achieves 20 Percent Improvement in PI-QUAL Scores for Prostate MRI
May 9th 2024Using a learning network model to discuss challenges and share insights among radiology departments from five different organizations, researchers noted that 87 percent of audited prostate MRI exams had PI-QUAL scores > 4 at the conclusion of the collaborative program.